US EditionNovo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50%
Novo Nordisk will reduce list prices for Wegovy by 50% and Ozempic by 35% to $675 monthly starting Jan. 1, 2027, aiming to improve insured patients' access.
- Novo Nordisk announced a cut to U.S. list prices for Ozempic, Rybelsus and Wegovy to $675 for a one-month supply, effective Jan. 1, 2027.
- On Feb. 23, Novo released head-to-head trial results showing CagriSema produced 23% weight loss over 84 weeks versus 25.5% for tirzepatide, and Novo Nordisk shares fell 16% on Monday.
- The company says the list-price change targets insurance-based cost-sharing, with Miller stating, `We think this addresses and responds to repeated call for lower list prices...`
- Cash-Paying customers, however, will largely see no change since Wegovy's list price remains $1,349 and some direct-purchase cash prices were already cut to $349; Novo recently sued telehealth company Hims & Hers, with John Kuckelman, Novo Nordisk group general counsel, warning others.
- About 7 in 10 people who've taken GLP-1 medications said cost influenced their treatment decisions, and Navitus Health Solutions found 1 in 4 paid more than $250 per fill; Sharon Faust said, `Difficult tradeoffs exist for patients and plan sponsors alike.
40 Articles
40 Articles
Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027
Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and Rybelsus by up to half starting in 2027.
The Danish pharmaceutical company continues to fuel competition with US competitor Eli Lilly. Novo Nordisk reduces the prices for obesity therapy Wegovy by about half.
In the face of dungeon sales, the Danish company announced on Tuesday a decrease of between 35 and 50 % in the prices of its flagship drugs overseas, its main market, from.
ABC FOX Montana
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
Coverage Details
Bias Distribution
- 55% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
